Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, develops medicines for common disorders of the central nervous system. The company's lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, a Phase III clinical stage for the treatment of PTSD; and Phase II clinical stage for the treatment of military-related PTSD. The company also develops TNX-301, a fixed dose combination drug product that contains disulfiram and selegiline for the treatment of alcohol use disorders, as well as biodefense development programs for protection from smallpox virus and radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.